We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford Gene Technology Grants Microarray License to Ocean Ridge Biosciences for Microarray Services
News

Oxford Gene Technology Grants Microarray License to Ocean Ridge Biosciences for Microarray Services

Oxford Gene Technology Grants Microarray License to Ocean Ridge Biosciences for Microarray Services
News

Oxford Gene Technology Grants Microarray License to Ocean Ridge Biosciences for Microarray Services

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Gene Technology Grants Microarray License to Ocean Ridge Biosciences for Microarray Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology (OGT) and Ocean Ridge Biosciences (ORB) have announced the completion of a licence agreement granting ORB access to one of OGT’s “Southern array patents”, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.

The granted license will enable ORB to offer complete DNA expression and microRNA profiling services, worldwide, from its US operations in Jupiter, Florida.

Sue Sutton, Vice President Licensing North America, at OGT said: “Successful discussions with ORB have concluded with the granting of this license thus enabling the company to expand their customer base and add to OGT’s growing portfolio of North American licensees.”

Senior Scientist at ORB, David Willoughby, Ph.D. is pleased with the progress of the biotechnology company, commenting: “We appreciate the opportunity to provide this fundamental invention of Edwin Southern to the general research community, both locally here in Florida and throughout the U.S. and Canada. The licence will enable us to continue with our mission of improving human health through the provision of accurate, affordable, and information-rich genomic services.”

The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.

Advertisement